Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Is it time to sell Antibe Therapeutics to Big Pharma?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(169)
•••
Comment by mstrmndon Aug 03, 2021 5:25pm
281 Views
Post# 33646067

RE:RE:RE:Is it time to sell Antibe Therapeutics to Big Pharma?

RE:RE:RE:Is it time to sell Antibe Therapeutics to Big Pharma?

Well wouldn't it be the perfect way to sabotage an NSAID industry-wide competitor to force accepting a low-ball offer?

Don't be stupid, 5 years later, we know a lot more about liver enzyme elevation in ATB-346 (Otenaproxesul) than in 2015 including at 250 mg, 200 mg, 150 mg, 100 mg, and 75 mg

5x upper limit of normal for liver enzymes, is actually NOT that high, it's just the study protocol for mandatory reporting, if you binge drink on weekends your liver enzymes are probably 10x upper limit normal, remember 1/20 on random sampling will be abnormal based on how we define "normal"

So...Is it time to sell Antibe Therapeutics to Big Pharma?

topadvisor1 wrote: OH TOO FUNNY. YOU TWO ARE DREAMING IN TECHNICOLOR. LOL
HEHEHEHEHEHEHEHE
ight now, you would and should consode yourselves EXTREMELY LUCKY if ANYONE even offered just your cash position. STILL LOWER to where this is now. 


 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities